NTRK1 and medullary thyroid gland carcinoma: Although both have been approved for the treatment of advanced metastatic MTC [2], [3] and are undergoing Phase II trials in LAD [4], [5], RET inhibition is a secondary pharmacology of these drugs, which were initially developed as inhibitors of other receptor tyrosine kinases.